MDT

95.61

+0.82%↑

VEEV

300.34

+2.34%↑

A

138.64

-0.03%↓

HQY

89.66

-1.24%↓

PHR.US

22.83

+1.69%↑

MDT

95.61

+0.82%↑

VEEV

300.34

+2.34%↑

A

138.64

-0.03%↓

HQY

89.66

-1.24%↓

PHR.US

22.83

+1.69%↑

MDT

95.61

+0.82%↑

VEEV

300.34

+2.34%↑

A

138.64

-0.03%↓

HQY

89.66

-1.24%↓

PHR.US

22.83

+1.69%↑

MDT

95.61

+0.82%↑

VEEV

300.34

+2.34%↑

A

138.64

-0.03%↓

HQY

89.66

-1.24%↓

PHR.US

22.83

+1.69%↑

MDT

95.61

+0.82%↑

VEEV

300.34

+2.34%↑

A

138.64

-0.03%↓

HQY

89.66

-1.24%↓

PHR.US

22.83

+1.69%↑

Search

ENANTA PHARMACEUTICALS INC

Closed

SectorHealthcare

10.33 -2.73

Overview

Share price change

24h

Current

Min

10.07

Max

10.9

Key metrics

By Trading Economics

Income

4.4M

-18M

Sales

3.4M

18M

Profit margin

-99.678

Employees

131

EBITDA

5.6M

-15M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+72.76% upside

Dividends

By Dow Jones

Next Earnings

24 Nov 2025

Market Stats

By TradingEconomics

Market Cap

185M

324M

Previous open

13.06

Previous close

10.33

News Sentiment

By Acuity

35%

65%

104 / 371 Healthcare

Technical Score

By Trading Central

Confidence

Strong Bearish Evidence

ENANTA PHARMACEUTICALS INC Chart

Past performance is not a reliable indicator of future results.

Related News

2 Oct 2025, 23:30 UTC

Hot Stocks

Stocks to Watch: Rumble, Applied Materials, American Outdoor Brands

2 Oct 2025, 21:21 UTC

Earnings

Applied Materials Expects New Export Rule to Hit 2026 Revenue by $600 Million

3 Oct 2025, 00:00 UTC

Acquisitions, Mergers, Takeovers

Warren Buffett's Berkshire Comes to the Aid of Occidental Petroleum -- Again -- WSJ

2 Oct 2025, 23:40 UTC

Market Talk

Gold Edges Higher, Aided by Risks U.S. Shutdown May Weaken Economy -- Market Talk

2 Oct 2025, 23:39 UTC

Market Talk

Japanese Stocks May Edge Higher, Tracking Wall Street Gains -- Market Talk

2 Oct 2025, 23:29 UTC

Acquisitions, Mergers, Takeovers

Vistra: Transaction Remains on Track to Close This Qtr or 1Q 2026 >VST

2 Oct 2025, 23:29 UTC

Acquisitions, Mergers, Takeovers

Vistra: Received Regulatory Approval From FERC for Acquisition of Certain Subsidiaries Owning Seven Natural-Gas Generation Facilities From Lotus Infrastructure Partners >VST

2 Oct 2025, 23:29 UTC

Acquisitions, Mergers, Takeovers

Vistra: Next Step in Acquisition of Gas Generation Fleet With Approval From Federal Energy Regulatory Commission

2 Oct 2025, 23:00 UTC

Market Talk

Warehouse Needs Time to Restore Credibility With Investors -- Market Talk

2 Oct 2025, 22:54 UTC

Market Talk
Acquisitions, Mergers, Takeovers

Scales's JV Buyout Lauded by Bull -- Market Talk

2 Oct 2025, 22:54 UTC

Market Talk
Acquisitions, Mergers, Takeovers

Global Forex and Fixed Income Roundup: Market Talk

2 Oct 2025, 22:46 UTC

Market Talk

Synlait Milk Loses Bear Following Sale of North Island Assets -- Market Talk

2 Oct 2025, 22:46 UTC

Market Talk

Global Equities Roundup: Market Talk

2 Oct 2025, 21:17 UTC

Acquisitions, Mergers, Takeovers

Buffett Scores Win in Berkshire's Deal for Occidental Chemicals Unit -- Barrons.com

2 Oct 2025, 20:50 UTC

Market Talk
Acquisitions, Mergers, Takeovers

Energy & Utilities Roundup: Market Talk

2 Oct 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

2 Oct 2025, 20:49 UTC

Acquisitions, Mergers, Takeovers

OpenAI's Latest Funding Deal Returns Focus to AI Economy, Lifting U.S. Stocks -- WSJ

2 Oct 2025, 20:00 UTC

Acquisitions, Mergers, Takeovers

Legrand Signs Definitive Agreement To Acquire Avtron Power Solutions, A Global Provider Of Load Banks & Power Quality Solutions >LR.FR

2 Oct 2025, 19:20 UTC

Market Talk

Natural Gas Snaps Winning Streak Despite Small Inventory Rise -- Market Talk

2 Oct 2025, 19:10 UTC

Market Talk

Bank of Canada to Publish Inflation Dashboard in 2026 -- Market Talk

2 Oct 2025, 19:04 UTC

Market Talk

Oil Futures Extend Losses as Markets Brace for Higher Output -- Market Talk

2 Oct 2025, 18:46 UTC

Acquisitions, Mergers, Takeovers

Honeywell: Transaction Expected to Improve Annual Free Cash Flow by More Than $100 M Over Next Several Years and Then Decrease Over Time >HON

2 Oct 2025, 18:46 UTC

Acquisitions, Mergers, Takeovers

Honeywell: Loss Will Be Excluded From Adjusted EPS >HON

2 Oct 2025, 18:46 UTC

Acquisitions, Mergers, Takeovers

Honeywell: Estimated Impact of Divestiture Will Be One-Time Loss of About $115 M >HON

2 Oct 2025, 18:45 UTC

Acquisitions, Mergers, Takeovers

Honeywell Will Have No Further Fincl Exposure to the Transferred Liabilities >HON

2 Oct 2025, 18:45 UTC

Acquisitions, Mergers, Takeovers

Honeywell Utilized Portion of Cash From Resideo Indemnification and Reimbursement Agreement Termination to Fund Delticus Transaction >HON

2 Oct 2025, 18:44 UTC

Acquisitions, Mergers, Takeovers

Honeywell: Delticus Assumed Full Responsibility for Administering and Resolving All Current and Future Asbestos-Related Claims >HON

2 Oct 2025, 18:44 UTC

Acquisitions, Mergers, Takeovers

Honeywell and Delticus Contributed About $1.68 B in Cash, as Well as Certain Insurance Assets Related to Legacy Asbestos Liabilities >HON

2 Oct 2025, 18:44 UTC

Acquisitions, Mergers, Takeovers

Honeywell: Transaction Strengthens Annual Free Cash Flow Generation >HON

2 Oct 2025, 18:43 UTC

Acquisitions, Mergers, Takeovers

Honeywell Divested All Legacy Bendix Asbestos Liabilities, as Well as Certain Non-Bendix Asbestos Liabilities, to Delticus >HON

Peer Comparison

Price change

ENANTA PHARMACEUTICALS INC Forecast

Price Target

By TipRanks

72.76% upside

12 Months Forecast

Average 18.33 USD  72.76%

High 25 USD

Low 9 USD

Based on 6 Wall Street analysts offering 12 month price targets forENANTA PHARMACEUTICALS INC - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

6 ratings

5

Buy

1

Hold

0

Sell

Technical Score

By Trading Central

5.04 / 5.44Support & Resistance

Short Term

Strong Bearish Evidence

Intermediate Term

Weak Bearish Evidence

Long Term

No Evidence

Sentiment

By Acuity

104 / 371 Healthcare

News Sentiment

Bullish Evidence

Volatility

Below average

News Volume (RCV)

Above average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About ENANTA PHARMACEUTICALS INC

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. The company has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. Enanta Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in Watertown, Massachusetts.
help-icon Live chat